CoronaryAtlas logo
CoronaryAtlas
Total cholesterol
Pathway / Lipid retention & oxidation

Total cholesterol

lipid

Circulating total cholesterol, particularly in apoB-lipoproteins, drives subendothelial lipid retention and plaque formation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationalePrimary atherogenic lipid burden; CAD risk correlation.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — non-Type-I
46
A — assay feasibility
40
E — evidence strength
80
T1DI (composite)
11
Specificity differential (R−C)-30.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 1
4bstent thrombosismag 1
4cin-stent restenosismag 1
5CABG-relatedn/a
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 24 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(5)

Clinical trials(1)